 RUTHERFORD, N.J., Feb. 01, 2021 GLOBE NEWSWIRE -- Cancer Genetics, Inc. the Company Nasdaq: CGIX, a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced private placement of approximately 10.0 million through the issuance of an aggregate 2,758,624 shares of its common stock and warrants to purchase up to an aggregate 2,758,624 shares of common stock, at a combined purchase price of 3.625 per share of common stock and associated warrant in a private placement priced at-the-market under Nasdaq rules. 